Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celator Pharma, Cephalon to extend research pact
Under the agreement, Cephalon will use Celator’s proprietary technology in an ongoing drug development and life-cycle management program at Cephalon. Celator Pharma CEO Scott Jackson said they are
Under the agreement, Cephalon will use Celator’s proprietary technology in an ongoing drug development and life-cycle management program at Cephalon. Celator Pharma CEO Scott Jackson said they are
Regorafenib is an oral multi-kinase inhibitor, which targets angiogenic (VEGFR, TIE-2), stromal (PDGFR-ß) and oncogenic (RAF, RET and KIT) receptor tyrosine kinases. The randomised, double-blind, placebo-controlled, multi-centre, cross-over
A pivotal phase III trial of XL184 in patients medullary thyroid cancer (MTC) in currently being conducted. Exelixis expects to release top-line phase III results in the first-half
In the single dose, single-site, randomised, placebo- and active-controlled study, 135 subjects received Vyvanse 20mg, 50mg, 70mg, placebo or the active comparator (armodafinil 250mg (NUVIGIL)). On the primary
Reportedly, the company has recruited first patient in September 2010. In the trial, the patients are expected to receive immunization over a period of six months, with the
With this, Mannatech will now hold 12 patents for technology related to Ambrotose AO in Australia, Mexico, New Zealand, Singapore, South Africa and South Korea. Mannatech co-CEO and
GSK and Galapagos signed the arthritis alliance in June 2006 for the discovery and development of disease-modifying drugs for GSK’s global R&D organization. In the trial, GLPG0555 was
The proposal combines IDRI’s vaccine-adjuvant technology and a micro-needle delivery device to create a device-adjuvant platform. The platform will have the potential for intra-dermal delivery of a variety
The idea is to gain accreditations allowing the packing of controlled drugs. Wasdell Packaging has also ordered new kits for the scanning and printing of 2D data matrixes
Resolvyx Pharma has scheduled RX-10045 Phase III randomized, placebo-controlled, multi-center study in 2011. Under the agreement, Celtic Therapeutics may also license rights to and develop a second Resolvyx